Fosun Swings to Book Loss with Asset Impairments, Targets Profit Recovery

  • Fosun International reported RMB173.43 billion in total revenue for 2025, with 54.7% coming from overseas markets.
  • The company recorded a RMB23.4 billion book loss primarily due to non-cash impairment provisions on real estate and non-core assets (55% real estate, 45% non-core).
  • Fosun Pharma, a core subsidiary, achieved a 21.69% year-on-year increase in net profit attributable to shareholders, reaching RMB3.371 billion.
  • Fosun aims to restore annual profit to around RMB10 billion, recover RMB60 billion in cash, and reduce total debt to below RMB60 billion.
  • The company plans to increase its dividend payout ratio to 35% for the 2026 financial year, with expected dividends of at least HKD1.5 billion.

Fosun's announcement reveals a strategic shift towards prioritizing core businesses and shedding underperforming assets, a move likely driven by recent market volatility and regulatory pressures. The substantial book loss underscores the challenges of managing a diversified conglomerate, particularly one with significant real estate exposure. This restructuring aims to position Fosun for more sustainable growth, but the success of this pivot will depend on its ability to execute decisively and capitalize on opportunities in its core sectors like pharmaceuticals and wealth management.

Profitability
Whether Fosun can achieve its stated RMB10 billion profit target, given the significant impairments already recognized, will hinge on the performance of its core businesses and the effectiveness of its streamlining efforts.
Asset Management
The pace at which Fosun can divest or restructure its remaining non-core assets will be a key indicator of its commitment to a leaner operating model and its ability to unlock value.
Regulatory Risk
How Fosun navigates evolving regulatory landscapes in China and key international markets, particularly concerning its pharmaceutical and insurance businesses, will significantly impact its long-term growth prospects.